Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase – Here’s Why

Upstream Bio, Inc. (NASDAQ:UPB) shares saw unusually-high trading volume on Friday . Approximately 2,234,547 shares were traded during trading, an increase of 114% from the previous session’s volume of 1,042,253 shares.The stock last traded at $9.8690 and had previously closed at $12.80.

Wall Street Analysts Forecast Growth

UPB has been the subject of a number of research analyst reports. Evercore started coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective for the company. Lifesci Capital initiated coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Price Performance

The firm has a market capitalization of $484.25 million, a price-to-earnings ratio of -4.67 and a beta of 1.90. The business has a 50 day moving average of $28.63 and a 200 day moving average of $23.22.

Hedge Funds Weigh In On Upstream Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in UPB. Invesco Ltd. increased its position in shares of Upstream Bio by 6.4% during the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after purchasing an additional 985 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Upstream Bio during the fourth quarter worth about $29,000. Torren Management LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth approximately $30,000. JPMorgan Chase & Co. raised its stake in shares of Upstream Bio by 8.4% in the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after acquiring an additional 1,275 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Upstream Bio by 2.8% in the third quarter. Rhumbline Advisers now owns 49,406 shares of the company’s stock valued at $929,000 after acquiring an additional 1,340 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.